French healthcare company Sanofi announced on Wednesday positive data for its frexalimab product aimed at treating multiple sclerosis, and that the firm plans to initiate pivotal trials in multiple sclerosis in early 2024.
Sanofi announces positive data for frexalimab product to treat multiple sclerosis
File Photo: Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. REUTERS/Benoit Tessier
&uuid=(email))